Trial Profile
Combined Dietary Supplementation With Lactobacillus Reuteri and Omega-3 PUFA During Pregnancy and Postnatally in Relation to Development of IgE-associated Disease During Infancy.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Limosilactobacillus reuteri (Primary) ; Omega-3-fatty-acid (Primary) ; Omega 3 fatty acids
- Indications Food hypersensitivity; Immediate hypersensitivity
- Focus Therapeutic Use
- Acronyms PROOM-3
- 09 Mar 2012 New trial record